Details : BioEclipse is performing a Phase 1 clinical study evaluating the safety and tolerability of CRX100, a first-in-class immunotherapy that pairs the power of an oncolytic virus with the tumor-locating ability of cytokine-induced killer (CIK) cells.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
April 26, 2022
Details : This open-label, Phase 1 dose-escalation study is to determine the safety, tolerability, and pharmacokinetic (PK) properties of CRX100 in up to 24 participants 18 years or older with advanced solid tumors that do not respond to standard of care.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
January 19, 2021
Bioeclipse Initiates Enrollment in Phase 1 Dose-Escalation Clinical Trial for CRX100
Details : The trial marks the first-in-human study of CRX100, an intravenously-delivered cancer therapy designed to target and destroy multiple cancer types and address disease recurrence.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
December 21, 2020
BioEclipse Receives FDA Clearance of Investigational New Drug Application for CRX100
Details : This multi-mechanistic cancer immunotherapy is delivered intravenously to target and destroy multiple cancer types and to prevent disease recurrence.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
April 28, 2020
Details : CRX100 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
February 24, 2020
Reset All
